Oxford BioMedica plc (OXBDF)
OTHER OTC:OXBDF
OXBDF Stock Chart & Stats
$7.90
-$0.05(-0.85%)
At close: 4:00 PM EST
$7.90
-$0.05(-0.85%)
Day’s Range― - ―
52-Week Range$3.15 - $13.15
Previous CloseN/A
Volume1.00K
Average Volume (3M)3.47K
Market Cap
$917.11M
Enterprise Value$701.13M
Total Cash (Recent Filing)$96.88M
Total Debt (Recent Filing)$106.64M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Sep 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding120,900,850
10 Day Avg. Volume8,533
30 Day Avg. Volume3,474
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)7.56
Price to Sales (P/S)4.09
P/FCF Ratio-67.62
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue4.16
Enterprise Value/Gross Profit10.63
Enterprise Value/Ebitda-45.40
Forecast
1Y Price Target
$13.22Price Target Upside67.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$3.05M
Bulls Say, Bears Say
Bulls Say
Order BookThe company's contracted order book reached approximately £186m in 2024, representing over a 30% increase year-over-year.
Revenue GrowthOXB delivered revenues of £128.8m, in line with its January trading update and previous guidance, representing 44% growth YoY.
Bears Say
Macroeconomic HeadwindsThere is a level of caution on the outlook due to uncertain macroeconomic headwinds and a tight funding environment.
Oxford BioMedica News
OXBDF FAQ
What was Oxford BioMedica plc’s price range in the past 12 months?
Oxford BioMedica plc lowest stock price was $3.15 and its highest was $13.15 in the past 12 months.
What is Oxford BioMedica plc’s market cap?
Oxford BioMedica plc’s market cap is $917.11M.
When is Oxford BioMedica plc’s upcoming earnings report date?
Oxford BioMedica plc’s upcoming earnings report date is Sep 23, 2026 which is in 162 days.
How were Oxford BioMedica plc’s earnings last quarter?
Oxford BioMedica plc released its earnings results on Mar 26, 2026. The company reported -$0.073 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.034.
Is Oxford BioMedica plc overvalued?
According to Wall Street analysts Oxford BioMedica plc’s price is currently Undervalued.
Does Oxford BioMedica plc pay dividends?
Oxford BioMedica plc does not currently pay dividends.
What is Oxford BioMedica plc’s EPS estimate?
Oxford BioMedica plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioMedica plc have?
Oxford BioMedica plc has 120,900,850 shares outstanding.
What happened to Oxford BioMedica plc’s price movement after its last earnings report?
Oxford BioMedica plc reported an EPS of -$0.073 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went down -1.873%.
Which hedge fund is a major shareholder of Oxford BioMedica plc?
Currently, no hedge funds are holding shares in OXBDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oxford BioMedica Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.22 (67.31% Upside)
$13.22 (67.31% Upside)
Blogger Sentiment
Bullish
OXBDF Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $306.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.37%
12-Months-Change
Fundamentals
Return on Equity
-48.56%
Trailing 12-Months
Asset Growth
51.01%
Trailing 12-Months
Company Description
Oxford BioMedica plc
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
OXBDF Company Deck
OXBDF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.View all OXBDF earnings summariesOXBDF Stock 12 Month Forecast
Average Price Target
$13.22
▲(67.31% Upside)
Technical Analysis
Avacta Group plc
―
PureTech Health
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Arecor Therapeutics PLC
―
Ownership Overview
Options Prices
Currently, No data available
---